Skip to main content
Quest Diagnostics Home

The CDC Clinical Practice Guideline for Prescribing Opiods for Pain

The CDC Clinical Practice Guideline for Prescribing Opiods for Pain

EPISODE SUMMARY

Welcome to the Quest Diagnostics “topics in drug testing” podcast. Today’s episode is with Quest Diagnostics senior medical advisor, Dr Jeff Gudin, and Dr Jack Kain, director and medical science liaison for the Quest Drug Monitoring and Toxicology business.

The podcast will cover:

  • Summary of the 2022 CDC Clinical Practice Guideline for Prescribing Opioids
    for Pain
  • Summary of key findings from the Quest Diagnostics Health Trends report,
    Drug Misuse in America 2022—A Decade Lost to the Drug Crisis

 

To listen to other podcasts in our Topics in Drug Testing series on Podbean.com, please visit QuestDrugTesting.com.

At Quest Diagnostics, we are committed to providing you results and insight to support your clinical decisions.

 

Want to listen to other episodes in the Topics in Drug Testing Podcast Series?

Audio Podcast
Ketamine: a re-emergence in medicine and misuse?
Audio Podcast
Windows of Detection
Audio Podcast
Contributing Factors to the Skyrocketing Drug Misuse Epidemic in the US

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA certified laboratories that provide HIPAA covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA covered services. 

 

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2023 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.